Molecular Oncology and Viral Pathology Group (CI-IPOP), Portuguese Oncology Institute of Porto, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Microbiology Service, Portuguese Oncology Institute of Porto, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
J Clin Virol. 2019 Oct;119:31-36. doi: 10.1016/j.jcv.2019.08.002. Epub 2019 Aug 2.
In developed countries, Hepatitis E virus (HEV) infections, especially by HEV-3, are frequently associated with asymptomatic infection or self-limiting acute hepatitis, although it has been described as a cause of chronic infection, especially in immunocompromised hots. Hematopoietic stem cell transplant (HSCT) recipients have been recognized as an important risk group for HEV infection due to their prolonged immunosuppression state.
We aimed to perform a systematic review of published data to evaluate HEV infection prevalence among HSCT recipients.
Literature search was performed concerning published manuscripts regarding 'hepatitis E virus AND stem cell transplantation' following the Preferred Reporting of Systematic Reviews and MetaAnalyses (PRISMA) guidelines. Statistical analysis was performed using the MetaXL software to estimate the overall prevalence of HEV infection according to the different diagnostic approaches (HEV RNA and anti-HEV IgM and/or IgG detection).
A total of 7 manuscripts were included for data analysis, with 6 studies performed in Europe and 1 study in China. Regarding HEV RNA detection, the overall HEV infection prevalence was 1.50% (95% CI: 0.70-2.60). The overall anti-HEV IgM seroprevalence was 2.00% (95% CI: 0.30-4.50), and anti-HEV IgG was 11.4% (95% CI: 1.80-26.3).
This systematic review reveals that the overall prevalence of HEV infection in HSCT patients differ according to the diagnostic, thus emphasizing the need of more studies to increase the data regarding prevalence and incidence in HSCT recipients.
在发达国家，戊型肝炎病毒（HEV）感染，尤其是 HEV-3，常与无症状感染或自限性急性肝炎相关，尽管它已被描述为慢性感染的原因，特别是在免疫功能低下的热点人群中。由于造血干细胞移植（HSCT）受者处于长期免疫抑制状态，因此已被认为是 HEV 感染的重要高危人群。
我们旨在对已发表的数据进行系统评价，以评估 HSCT 受者中 HEV 感染的流行率。
根据《系统评价和荟萃分析报告的首选报告》（PRISMA）指南，对有关“戊型肝炎病毒和干细胞移植”的已发表文献进行了文献检索。使用 MetaXL 软件进行统计分析，根据不同的诊断方法（HEV RNA 和抗-HEV IgM 和/或 IgG 检测）估计 HEV 感染的总体流行率。
共有 7 篇文献纳入数据分析，其中 6 项研究在欧洲进行，1 项在中国进行。关于 HEV RNA 检测，HEV 总体感染流行率为 1.50%（95%CI：0.70-2.60）。抗-HEV IgM 血清流行率为 2.00%（95%CI：0.30-4.50），抗-HEV IgG 为 11.4%（95%CI：1.80-26.3）。
本系统评价表明，HSCT 患者中 HEV 感染的总体流行率因诊断方法而异，因此强调需要更多的研究来增加有关 HSCT 受者中流行率和发病率的数据。
